All Oncology News

CAR-like T-cells, PD-1 inhibitor, and SOX was active in previously untreated metastatic gastric or GEJ adenocarcinoma.

ECOG performance status captured only part of the patient experience in advanced gastric or gastroesophageal junction adenocarcinoma.

Enolen, a localized enzalutamide–eluting implant, has received FDA fast track designation for low- to intermediate-risk, localized prostate cancer.

Pumitamig/nab-paclitaxel produced responses in advanced TNBC in a phase 2 study, informing its further evaluation in the phase 3 ROSETTA Breast-01 trial.

Orca-T improved clinical outcomes both overall and across patient subgroups with varied demographic and clinical features in the Precision-T trial.

Bone marrow Immune Atlas in myeloma linked immune system/tumor interactions with disease aggressiveness, potentially improving prognosis and risk stratification.

Total neoadjuvant chemotherapy plus chemoradiotherapy was identified as a preferred candidate for future study in resectable gastric adenocarcinoma.

Zolbetuximab plus mFOLFOX6 and nivolumab was effective and tolerable across biomarker-defined subgroups in unresectable gastric/GEJ adenocarcinoma.

HERIZON-GEA-01 is the first phase 3 study to demonstrate a median PFS greater than 1 year, and a median OS greater than 2 years in metastatic GEA.

R. Lor Randall, MD, FACS, discusses global variation in DAIR strategies for post–limb salvage infections, highlighting needs for standardization and multidisciplinary coordination.

FDA grants fast track designation to a PARG inhibitor, ETX-19477, for the treatment of BRCA-mutated, platinum-resistant HGSOC.

Zoldonrasib has received breakthrough therapy designation in pretreated KRAS G12D–mutated locally advanced or metastatic NSCLC.

Researchers discovered that the oncogene ERG triggers cancer by reprogramming prostate basal cells.

Preetesh Jain, MD, MBBS, DM, PhD, discusses data from real-world analysis of treatment patterns in high-risk mantle cell lymphoma and their implications.

Fangfang Yan, MD, discusses the place of CAR T-cell therapy in the MCL treatment paradigm and how AI can address drivers of CAR T-cell therapy resistance.

Tsewang Tashi, MD, expands on long-term bone health data with avapritinib in patients with indolent systemic mastocytosis from the PIONEER trial.

Phase 2 data showed atezolizumab plus bevacizumab led to limited responses in patients with metastatic colorectal cancer and an MSI-like gene signature.

MD Anderson and SOPHiA GENETICS announce a partnership focused on data-driven oncology tools for clinical practice.

CPI-008 received orphan drug designation from the FDA and EMA for margin detection of pancreatic cancer during surgery.

The first-in-class, CXCR4hi regulatory T-cell therapy CK0804 received orphan drug designation for patients with myelofibrosis.

Post hoc ARAMIS data showed that darolutamide improved MFS and OS in nmCRPC regardless of prior radical prostatectomy or radiotherapy.

Obinutuzumab plus zanubrutinib, pomalidomide, and venetoclax produced high response rates in high-risk MCL.

Preetesh Jain, MD, MBBS, DM, PhD, discusses data with an acalabrutinib-based regimen in high-risk mantle cell lymphoma from the WINDOW-3 trial.

Mahesh Swaminathan, MB, BS, discusses whether the addition of obinutuzumab after 1 year of acalabrutinib/venetoclax is safe and effective in CLL.

Sac-TMT plus pembrolizumab has earned breakthrough therapy designation in China in frontline EGFR- and ALK-negative PD-L1+ NSCLC.

The EMA is reviewing a Type II variation application to expand teclistamab’s label for use with SC daratumumab in relapsed/refractory myeloma.

Two gene mutations, IDH2 and SRSF2, work together to disrupt RNA editing, changing how blood cells develop in acute myeloid leukemia

Orca-T plus allogeneic CAR T-cell therapy may represent a rational treatment approach in high-risk B-cell malignancies.

Sacituzumab govitecan displayed efficacy in terms of PFS both with/without pembrolizumab in patients with untreated TNBC.

Here is your Q1 2026 preview spotlighting 5 FDA decisions to watch, including upcoming PDUFAs for tabelecleucel, pembrolizumab, and more.